Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 June 2021Website:
http://www.prokidney.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 04 Nov 2024 23:34:37 GMTDividend
Analysts recommendations
Institutional Ownership
PROK Latest News
WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in two upcoming healthcare conferences in November.
WINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the UBS Virtual Organ Restoration Day, which will be taking place on October 15, 2024.
WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentially preserve kidney function in patients with type 2 diabetes and advanced CKD.
WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Morgan Stanley 22nd Annual Global Healthcare Conference, being held in New York, NY on September 4-6, 2024.
WINSTON-SALEM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the second quarter ended June 30, 2024.
WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses. ProKidney expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company.
WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company's renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical and operational updates. Management will host a live webcast today at 8:00 a.m. ET to discuss the data.
ProKidney Corp. (NASDAQ:PROK ) Q3 2023 Results Conference Call November 14, 2023 8:00 AM ET Company Participants Dr. Glenn Schulman - SVP of IR Pablo Legorreta - Chairman of Board Dr. Tim Bertram - Co-Founder and Member of Scientific Advisory Board Dr. Bruce Culleton - Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citi Justin Zelin - BTIG Jonathan Miller - Evercore Jason Gerberry - Bank of America Operator Good morning, ladies and gentlemen, and welcome to the ProKidney Corporate Update Conference Call. At this time, all lines are in a listen-only mode.
The heavy selling pressure might have exhausted for ProKidney Corp. (PROK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ProKidney Corp. (PROK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
What type of business is ProKidney?
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
What sector is ProKidney in?
ProKidney is in the Healthcare sector
What industry is ProKidney in?
ProKidney is in the Biotechnology industry
What country is ProKidney from?
ProKidney is headquartered in United States
When did ProKidney go public?
ProKidney initial public offering (IPO) was on 30 June 2021
What is ProKidney website?
https://www.prokidney.com
Is ProKidney in the S&P 500?
No, ProKidney is not included in the S&P 500 index
Is ProKidney in the NASDAQ 100?
No, ProKidney is not included in the NASDAQ 100 index
Is ProKidney in the Dow Jones?
No, ProKidney is not included in the Dow Jones index
When was ProKidney the previous earnings report?
No data
When does ProKidney earnings report?
The next expected earnings date for ProKidney is 14 November 2024